Author:
Generoso Giuliano,Bensenor Isabela M.,Santos Raul D.,Staniak Henrique L.,Sharovsky Rodolfo,Santos Itamar S.,Goulart Alessandra C.,Jones Steven R.,Kulkarni Krishnaji R.,Blaha Michael J.,Toth Peter P.,Lotufo Paulo A.,Bittencourt Marcio S.
Funder
Brazilian Ministry of Health
Ministry of Science and Technology
Financiadora de Estudos e Projetos
CNPq
Reference45 articles.
1. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy;Mora;Circulation,2013
2. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges;Sampson;Curr Atheroscler Rep,2012
3. Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials;Naci;Eur J Prev Cardiol,2013
4. Effects of dalcetrapib in patients with a recent acute coronary syndrome;Schwartz;N Engl J Med,2012
5. Effects of torcetrapib in patients at high risk for coronary events;Barter;N Engl J Med,2007
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献